1-877-273-4498
Call Now for Expert Advice
 
 
  Free Mesothelioma Information Guide
 

Instant Download

More Details »

 

Please fill the form below:

First *
Last *
Email
Phone *
Address
City
State
Zip Code
Click Here to edit...


You Are Here: Mesothelioma Treatment » Obtaining Treatment » Leading Mesothelioma Doctors » David Jablons
 

Dr. David M. Jablons

Positions and Timeline

Dr. David M. Jablons is a mesothelioma doctor experienced in mesothelioma therapy and treatment.  His current appointments include Chief of General Thoracic Surgery and Ada Distinguished Professor in Thoracic Oncology at UCSF Medical Center as well as Program Leader of the Thoracic Oncology Program of the UCSF Helen Diller Family Comprehensive Cancer Center.

  • 1984 – M. D. from Albany Medical College of Union University
  • 1985 – 1985, Resident, General Surgery, Oak Knoll Naval Hospital, Oakland, CA
  • 1985 – 1986 and 1989 – 1991, Resident, General Surgery, Tufts University/New England Medical Center
  • 1986 – 1989, Fellow, Surgical Oncology, Surgical Branch, NCI/NIH
  • 1991 – 1993, Fellow, Cardiothoracic Surgery, Cornell University Medical Center
  • 1992 , Fellow, Lung Transplantation, Brigham & Women's Hospital
  • Fellow, Thoracic Surgery, New York Hospital/Memorial Sloan Kettering Cancer Center

Research and Topics of Interest:

Dr. Jablons is a world renowned expert in lung cancer and mesothelioma including mesothelioma treatment and therapy.  Important projects include the Wnt pathway and mesothelioma, isolation of lung cancer stems cells, lung cancer system genetics, and inflammation in lung cancinogenesis. 

He is also a world leader in clinical outreach and has founded and/or chairs a number of field conferences.

Selected publications include:

1. Fujii N, You L, Xu Z, Uematsu K, Shan J, He B, Mikami I, Edmondson LR, Neale G, Zheng J, Guy RK, Jablons DM. An Antagonist of Dishevelled Protein-Protein Interaction Suppresses {beta}-Catenin-Dependent Tumor Cell Growth. Cancer Res, Jan/15/2007;67(2):573-9.
2. Raz DJ, Glidden DV, Odisho AY, Jablons DM. Clinical characteristics and survival of patients with surgically resected, incidentally detected lung cancer. J Thorac Oncol, Feb/2007;2(2):125-30.
3. Clément G, Jablons DM, Benhattar J. Targeting the Wnt signaling pathway to treat Barrett's esophagus. Expert Opin Ther Targets, Mar/2007;11(3):375-389.
4. Brouchet L, Bauvin E, Marcheix B, Bigay-Game L, Renaud C, Berjaud J, Falcoze PE, Venissac N, Raz D, Jablons DM, Mazieres J, Dahan. Impact of Induction Treatment on Postoperative Complications in the Treatment of Non-Small Cell Lung Cancer, Journal of Thoracic Oncology, 03/2007.
5. Kim J, You L, Xu Z, Kuchenbecker K, Raz D, He B, Jablons D. Wnt inhibitory factor inhibits lung cancer cell growth. J Thorac Cardiovasc Surg, Mar/2007;133(3):733-7.

Academic and Professional Memberships

Dr. Jablon is a member of these professional organizations: the Society of Thoracic Surgeons, the American College of Chest Physicians, the American Association for Cancer Research, and the International Association for the Study of Lung Cancer (IASLC).

Contact:

UCSF Comprehensive Cancer Center
1600 Divisadero Street, 4th Floor
San Francisco, CA 94115

Phone:
415-885-3882

Fax:
415-353-7151


    Simon, Eddins & Greenstone, LLP (C) 2009.
Created by WSI.
Sitemap | Privacy Statement | Terms of Use & Disclaimer | Contact | Login